vs
Amneal Pharmaceuticals, Inc.（AMRX）与克瑞（CR）财务数据对比。点击上方公司名可切换其他公司
Amneal Pharmaceuticals, Inc.的季度营收约是克瑞的1.2倍（$814.3M vs $696.4M），克瑞净利率更高（9.6% vs 4.3%，领先5.3%），克瑞同比增速更快（24.9% vs 11.5%），Amneal Pharmaceuticals, Inc.自由现金流更多（$108.5M vs $-40.2M），过去两年克瑞的营收复合增速更高（14.8% vs 11.1%）
Amneal Pharmaceuticals是一家美国上市制药企业，核心业务涵盖仿制药及专科药物的研发、生产与分销，总部位于新泽西州布里奇沃特，是美国规模最大的仿制药生产商之一。
克瑞是总部位于美国康涅狄格州斯坦福德的工业产品企业，1855年由理查德·泰勒·克兰创立。公司曾是美国领先卫浴配件制造商，1990年出售该业务板块，1960年起逐步转型为多元化控股集团，当前核心业务涵盖航空航天与电子、工程材料、流体处理、控制系统四大板块，服务化工等多个行业领域。
AMRX vs CR — 直观对比
营收规模更大
AMRX
是对方的1.2倍
$696.4M
营收增速更快
CR
高出13.4%
11.5%
净利率更高
CR
高出5.3%
4.3%
自由现金流更多
AMRX
多$148.7M
$-40.2M
两年增速更快
CR
近两年复合增速
11.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $814.3M | $696.4M |
| 净利润 | $35.1M | $67.1M |
| 毛利率 | 36.5% | 40.4% |
| 营业利润率 | 13.8% | 14.4% |
| 净利率 | 4.3% | 9.6% |
| 营收同比 | 11.5% | 24.9% |
| 净利润同比 | 212.9% | -37.3% |
| 每股收益（稀释后） | $0.10 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRXCR
| Q1 26 | — | $696.4M | ||
| Q4 25 | $814.3M | $581.0M | ||
| Q3 25 | $784.5M | $589.2M | ||
| Q2 25 | $724.5M | $577.2M | ||
| Q1 25 | $695.4M | $557.6M | ||
| Q4 24 | $730.5M | $544.1M | ||
| Q3 24 | $702.5M | $548.3M | ||
| Q2 24 | $701.8M | $528.6M |
净利润AMRXCR
| Q1 26 | — | $67.1M | ||
| Q4 25 | $35.1M | $81.7M | ||
| Q3 25 | $2.4M | $91.4M | ||
| Q2 25 | $22.4M | $86.4M | ||
| Q1 25 | $12.2M | $107.1M | ||
| Q4 24 | $-31.1M | $81.0M | ||
| Q3 24 | $-156.0K | $77.3M | ||
| Q2 24 | $6.0M | $71.6M |
毛利率AMRXCR
| Q1 26 | — | 40.4% | ||
| Q4 25 | 36.5% | 41.6% | ||
| Q3 25 | 34.9% | 42.7% | ||
| Q2 25 | 39.5% | 42.0% | ||
| Q1 25 | 36.8% | 42.6% | ||
| Q4 24 | 36.0% | 40.9% | ||
| Q3 24 | 38.4% | 41.4% | ||
| Q2 24 | 35.6% | 40.0% |
营业利润率AMRXCR
| Q1 26 | — | 14.4% | ||
| Q4 25 | 13.8% | 17.5% | ||
| Q3 25 | 9.0% | 20.1% | ||
| Q2 25 | 15.4% | 17.8% | ||
| Q1 25 | 14.4% | 18.1% | ||
| Q4 24 | 10.4% | 15.8% | ||
| Q3 24 | 12.6% | 18.1% | ||
| Q2 24 | 13.6% | 16.9% |
净利率AMRXCR
| Q1 26 | — | 9.6% | ||
| Q4 25 | 4.3% | 14.1% | ||
| Q3 25 | 0.3% | 15.5% | ||
| Q2 25 | 3.1% | 15.0% | ||
| Q1 25 | 1.8% | 19.2% | ||
| Q4 24 | -4.3% | 14.9% | ||
| Q3 24 | -0.0% | 14.1% | ||
| Q2 24 | 0.9% | 13.5% |
每股收益（稀释后）AMRXCR
| Q1 26 | — | — | ||
| Q4 25 | $0.10 | $1.40 | ||
| Q3 25 | $0.01 | $1.56 | ||
| Q2 25 | $0.07 | $1.47 | ||
| Q1 25 | $0.04 | $1.83 | ||
| Q4 24 | $-0.10 | $1.37 | ||
| Q3 24 | $0.00 | $1.33 | ||
| Q2 24 | $0.02 | $1.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.0M | $355.4M |
| 总债务越低越好 | $2.6B | $1.2B |
| 股东权益账面价值 | $-70.8M | $2.1B |
| 总资产 | $3.7B | $4.1B |
| 负债/权益比越低杠杆越低 | — | 0.57× |
8季度趋势，按日历期对齐
现金及短期投资AMRXCR
| Q1 26 | — | $355.4M | ||
| Q4 25 | $282.0M | $506.5M | ||
| Q3 25 | $201.2M | $388.2M | ||
| Q2 25 | $71.5M | $332.2M | ||
| Q1 25 | $59.2M | $435.1M | ||
| Q4 24 | $110.6M | $306.7M | ||
| Q3 24 | $74.0M | $258.2M | ||
| Q2 24 | $43.8M | $229.3M |
总债务AMRXCR
| Q1 26 | — | $1.2B | ||
| Q4 25 | $2.6B | $1.1B | ||
| Q3 25 | $2.6B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.4B | $247.0M | ||
| Q3 24 | $2.4B | — | ||
| Q2 24 | $2.4B | — |
股东权益AMRXCR
| Q1 26 | — | $2.1B | ||
| Q4 25 | $-70.8M | $2.1B | ||
| Q3 25 | $-109.5M | $2.0B | ||
| Q2 25 | $-112.1M | $1.9B | ||
| Q1 25 | $-131.7M | $1.8B | ||
| Q4 24 | $-109.3M | $1.6B | ||
| Q3 24 | $-93.4M | $1.6B | ||
| Q2 24 | $-57.5M | $1.5B |
总资产AMRXCR
| Q1 26 | — | $4.1B | ||
| Q4 25 | $3.7B | $3.9B | ||
| Q3 25 | $3.6B | $2.5B | ||
| Q2 25 | $3.4B | $2.5B | ||
| Q1 25 | $3.4B | $2.6B | ||
| Q4 24 | $3.5B | $2.6B | ||
| Q3 24 | $3.5B | $2.7B | ||
| Q2 24 | $3.5B | $2.5B |
负债/权益比AMRXCR
| Q1 26 | — | 0.57× | ||
| Q4 25 | — | 0.56× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $130.3M | — |
| 自由现金流经营现金流 - 资本支出 | $108.5M | $-40.2M |
| 自由现金流率自由现金流/营收 | 13.3% | -5.8% |
| 资本支出强度资本支出/营收 | 2.7% | 1.5% |
| 现金转化率经营现金流/净利润 | 3.72× | — |
| 过去12个月自由现金流最近4个季度 | $269.9M | $361.5M |
8季度趋势，按日历期对齐
经营现金流AMRXCR
| Q1 26 | — | — | ||
| Q4 25 | $130.3M | $205.8M | ||
| Q3 25 | $118.5M | $130.2M | ||
| Q2 25 | $83.8M | $105.0M | ||
| Q1 25 | $7.4M | $-46.2M | ||
| Q4 24 | $118.1M | $202.0M | ||
| Q3 24 | $141.8M | $75.4M | ||
| Q2 24 | $39.7M | $51.3M |
自由现金流AMRXCR
| Q1 26 | — | $-40.2M | ||
| Q4 25 | $108.5M | $196.0M | ||
| Q3 25 | $106.2M | $116.8M | ||
| Q2 25 | $61.0M | $88.9M | ||
| Q1 25 | $-5.8M | $-60.4M | ||
| Q4 24 | $102.9M | $188.2M | ||
| Q3 24 | $124.8M | $67.3M | ||
| Q2 24 | $29.0M | $44.6M |
自由现金流率AMRXCR
| Q1 26 | — | -5.8% | ||
| Q4 25 | 13.3% | 33.7% | ||
| Q3 25 | 13.5% | 19.8% | ||
| Q2 25 | 8.4% | 15.4% | ||
| Q1 25 | -0.8% | -10.8% | ||
| Q4 24 | 14.1% | 34.6% | ||
| Q3 24 | 17.8% | 12.3% | ||
| Q2 24 | 4.1% | 8.4% |
资本支出强度AMRXCR
| Q1 26 | — | 1.5% | ||
| Q4 25 | 2.7% | 1.7% | ||
| Q3 25 | 1.6% | 2.3% | ||
| Q2 25 | 3.2% | 2.8% | ||
| Q1 25 | 1.9% | 2.5% | ||
| Q4 24 | 2.1% | 2.5% | ||
| Q3 24 | 2.4% | 1.5% | ||
| Q2 24 | 1.5% | 1.3% |
现金转化率AMRXCR
| Q1 26 | — | — | ||
| Q4 25 | 3.72× | 2.52× | ||
| Q3 25 | 50.00× | 1.42× | ||
| Q2 25 | 3.74× | 1.22× | ||
| Q1 25 | 0.61× | -0.43× | ||
| Q4 24 | — | 2.49× | ||
| Q3 24 | — | 0.98× | ||
| Q2 24 | 6.62× | 0.72× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRX
| Oral Solid | $188.7M | 23% |
| Distribution Service | $107.7M | 13% |
| Central Nervous System | $104.8M | 13% |
| Government Label | $86.8M | 11% |
| Other Dosage Forms | $68.2M | 8% |
| Transdermal | $56.1M | 7% |
| Hormonal Allergy | $47.6M | 6% |
| Ephinephrine Auto Injector | $39.1M | 5% |
| Injectable | $37.4M | 5% |
| Other | $33.6M | 4% |
| Biosimilar | $29.4M | 4% |
| Selling General And Administrative Expenses | $14.9M | 2% |
CR
| Process Flow Technologies | $378.1M | 54% |
| Aerospace & Advanced Technologies | $318.3M | 46% |
